TG Therapeutics, Inc. News Releases http://ir.tgtherapeutics.com/ TG Therapeutics, Inc. News Releases en TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-data-presentations-upcoming-medical Presentations include four oral and two poster presentations across three medical meetings in June NEW YORK , May 16, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 55 th American Society of Clinical Oncology ( ASCO Thu, 16 May 2019 07:30:00 -0400 TG Therapeutics, Inc. News Releases 15116 TG Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-provides-business-update-and-reports-first Conference Call to be held today, Friday, May 10, 2019 at 8:00 AM ET NEW YORK , May 10, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the first quarter ended March 31, 2019 and recent company developments. Michael S. Fri, 10 May 2019 07:00:00 -0400 TG Therapeutics, Inc. News Releases 15096 TG Therapeutics to Host Conference Call on First Quarter 2019 Financial Results and Business Update http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-host-conference-call-first-quarter-2019 Conference Call to be held Friday, May 10, 2019 at 8:00 AM ET NEW YORK , May 09, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Friday, May 10, 2019 at 8:00 AM ET to discuss results for the first quarter of 2019 and provide a Thu, 09 May 2019 07:30:00 -0400 TG Therapeutics, Inc. News Releases 15086 TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis at the American Academy of Neurology 71st Annual Meeting http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-long-term-follow-data-phase-2-trial Ublituximab treatment continues to be well tolerated with a median duration of follow-up of 97.5 weeks NEW YORK , May 07, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today Tue, 07 May 2019 09:00:00 -0400 TG Therapeutics, Inc. News Releases 15076 TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Marginal Zone Lymphoma http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-receives-orphan-drug-designation-umbralisib-us NEW YORK , April 15, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics , Inc. (NASDAQ: TGTX) today announced that the U.S. Food and Drug Administration ( FDA ) granted orphan drug designation to its phosphoinositide-3-kinase (PI3K) delta inhibitor, umbralisib (TGR-1202), for the treatment of patients with Mon, 15 Apr 2019 07:30:00 -0400 TG Therapeutics, Inc. News Releases 15061 TG Therapeutics to Present at the 18th Annual Needham Healthcare Conference http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-present-18th-annual-needham-healthcare Presentation scheduled for Tuesday, April 9, 2019, at 4:50PM ET NEW YORK , April 05, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, will present at the 18 th Annual Needham Fri, 05 Apr 2019 07:30:00 -0400 TG Therapeutics, Inc. News Releases 15056 TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-reports-positive-interim-data-unity-nhl-phase-2b Overall response rate ( ORR ) of 52% (N=42), with complete response (CR) rate of 19%, by central independent review committee (IRC)  Responses were durable, with median duration of response (DOR) not reached at median 12.5 months follow-up, and all patients in complete response remain on study Mon, 01 Apr 2019 08:30:00 -0400 TG Therapeutics, Inc. News Releases 15031 TG Therapeutics to Present Interim Data from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the Upcoming 2019 AACR Annual Meeting http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-present-interim-data-unity-nhl-phase-2b-trial Abstract and full presentation will be publicly available Monday April 1, 2019 at 8:30am ET Company to host conference call on Monday, April 1, 2019 at 12:00pm (noon) ET, with Dr. Nathan Fowler of MD Anderson Cancer Center and Study Chair of the MZL cohort NEW YORK , March 29, 2019 (GLOBE NEWSWIRE) Fri, 29 Mar 2019 16:00:00 -0400 TG Therapeutics, Inc. News Releases 15026 TG Therapeutics, Inc. Announces Data Presentation at the Upcoming American Academy of Neurology 71st Annual Meeting http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-inc-announces-data-presentation-upcoming-1 NEW YORK , March 12, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that data from the Phase 2 multicenter trial evaluating ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS) has Tue, 12 Mar 2019 08:00:00 -0400 TG Therapeutics, Inc. News Releases 15021 TG Therapeutics to Present at the Cowen 39th Annual Health Care Conference http://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-present-cowen-39th-annual-health-care-conference Presentation scheduled for Wednesday, March 13, 2019, at 11:20 AM ET NEW YORK , March 11, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, will present at the 39 th Annual Cowen Mon, 11 Mar 2019 03:26:00 -0400 TG Therapeutics, Inc. News Releases 15006